The present invention relates generally to medical equipment, and more particularly to devices for controlling and dispensing medicament to a patient.
Precise infusion of large volumes of liquid medicament through an administration line is usually accomplished by an infusion pump. Traditional infusion pumps make use of a flexible infusion bag suspended above the patient. For many medicaments and drugs, a pharmacist, nurse, doctor, or other medical professional is required to prepare the infusion bag by reconstituting, diluting, and/or mixing the medicament or drug in preparation for its delivery and use with a pump. Such methods are cumbersome, imprecise, require many time-consuming steps by medical professionals, are susceptible to medication errors and require bed confinement of the patient. Periodic monitoring of the apparatus by a nurse, doctor, or other medical professional is required to detect malfunctions of the infusion pump. Accordingly, over the years, infusion pumps developed into increasingly more complex devices which are expensive and sophisticated. Such devices include a large number of features, options, and programmability possibilities. While those capabilities can be advantageous in providing a range of customization to medicament administration, they also lead to use error, and the possibility of patient harm, injury, or death.
Complicated infusion pumps also typically require many time-consuming steps for setup, including applying both a medicament reservoir and administration line to the pump. Increased preparation requirements increase the risk of contaminating the pump, the medicament reservoir, the administration line, or other elements of the intravenous line system. An improved system for providing a convenient and sterile infusion of large volumes of medicament is needed.
A liquid medicament dosage control and delivery device includes an aseptic fluid communication path from a liquid medicament reservoir to an administration line that can be stored and delivered without risk of contamination. The reservoir of the device is filled with a liquid medicament and sterilized before assembly into the device. The fluid communication path includes a tubing set and the administration line which are also sterilized and then coupled to the pre-filled reservoir with an aseptic connector that prevents contamination. The aseptic connector includes a barrier preventing liquid medicament from flowing into the tubing set until the barrier is removed. Removal of the barrier from the aseptic connector both couples the reservoir in fluid communication with the tubing set and energizes the device with power so that the device may be used to safely deliver contaminant-free liquid medicament to a patient.
Referring to the drawings:
Reference now is made to the drawings, in which the same reference characters are used throughout the different figures to designate the same elements.
The housing 11 has a generally teardrop shape and, in the embodiment shown in
The front panel 14 is formed with an axial slot defining a window 22 through the housing 10 in which a medicament reservoir 23 (referred to hereinafter as both “reservoir 23” and “medicament reservoir 23”) carried inside the device 10 is observable. The window 22 is located between opposed sides 24 and 25 of the device 10 and extends from proximate the top 20 of the device to a location intermediate between the top 20 and bottom 21. The window 22 has parallel sides and a curved top and curved bottom.
The front panel 14 has a flat face 30 on which is mounted a panel 31 carrying control information for displaying and controlling the operation of the device 10. The panel 31 surrounds a lower portion of the window 22 and extends between the sides 24 and 25 and from a location intermediate between the top 20 and bottom 21 to the bottom 21. Proximate to the side 24 (which may be referred to herein as “the left side 24”), the panel 31 includes a first icon 32 grouped together with a pair of buttons 33. The first icon 32, in the embodiment shown in
Proximate to the side 25 (which may be referred to herein as “the right side 25”), the panel 31 includes a second icon 40 grouped together with a pair of buttons 41. The second icon 40, in the embodiment shown in
Turning to
An axially-extending slot defining a window 50 is formed through the rear top panel 15 in which the medicament reservoir 23 carried inside the device 10 is observable. The window 50 is located between opposed sides 24 and 25 of the device 10 and extends from proximate the top 20 of the device to a location intermediate between the top 20 and the seam 45. The window 22 has parallel sides and a curved top and curved bottom. The reservoir 23 is preferably transparent or translucent, allowing a user to see entirely through the reservoir 23 through the housing 10 at the windows 22 and 50, or allowing the reservoir 23 to be backlit through one of the windows 22 or 50.
The seam 45 is formed between abutting edges of the rear top and rear bottom panels 15 and 16, which may overlap in a snap-fit or other engagement. A pull assembly 51 is routed through the housing 10 and threaded through a slit 52 formed at an intermediate location in the seam 45 of the housing 10. The pull assembly 51 includes a two-ply ribbon 53 extending from within the housing where the two-ply ribbon 53 is coupled mechanically and electrically to irreversibly arrange the device 10 from a storage state to an operation state, as will be explained in detail below. Arranging the aseptic connector assembly 63 from the storage state to the use state is irreversible. The pull assembly 51 further includes a pull tab 54 at the distal end of the two-ply ribbon 53.
Turning now to
A fluid communication path 62 is carried by the device 10 to deliver liquid medicament to a patient. The fluid communication path 62 has a number of components including, from an upstream to a downstream location, the medicament reservoir 23, an aseptic connector assembly 63, a tubing set 64, and the administration line 12. The fluid communication path 62 is a sterile pathway for delivering liquid medicament to a patient, and maintains a sterile pathway during storage, distribution, shipping, delivery, preparation, and setup for use with a patient. The fluid-contacting portions, or the internal portions, of each of the components of the fluid communication path 62, namely, the medicament reservoir 23, an aseptic connector assembly 63, a tubing set 64, and the administration line 12 are sterilized prior to assembly, and the device 10 are assembled carefully to maintain the fluid-contacting portions in an aseptic manner, so that the device 10 provides for delivering a unit-dose of the medicament to a patient safely. Preferably, and as described in detail later, the medicament reservoir 23 containing the medicament and a portion of the aseptic connector assembly 63 are sterilized separately from another portion of the aseptic connector assembly 63, the tubing set 64, and the administration line 12, and the fluid communication path 62 is then assembled into the housing 11 with the other various structural elements and features carried by the housing which interact with the fluid communication path 62 to store, power, operate, and control the device 10.
Still referring to
Coupled to the tip 72 of the reservoir 23 is the aseptic connector assembly 63, best seen in the enlarged view of
A cylindrical, coaxial seat 90 is formed into a lower face 91 of the upper aseptic connector 80 opposite the post 83. The seat 90 communicates with the hole 86. An annular gasket 92 is received in the seat 90, the inner diameter of which is commensurate with that of the hole 86. The gasket 92 has a height just slightly greater than the depth of the seat 90, so that the gasket 92 protrudes slightly beyond the lower face 91. The gasket 92 is constructed from a material or combination of materials having characteristics of inertness, low permeability, durability, and compressibility, such as rubber. A thin film 93 is applied over the gasket 92 and is adhered and sealed to the lower face 91 of the upper aseptic connector 80. The thin film 93 completely overlies the gasket 92 with a continuous, closed-loop seal formed between the thin film 93 and the lower face 91 to act as a barrier to fluid migration.
The lower aseptic connector 81 is similar, but not identical, to the upper aseptic connector 80. Still referring to
A cylindrical, coaxial seat 102 is formed into an upper face 103 of the lower aseptic connector 81 opposite the post 95. The seat 102 communicates with the bore 101. An annular gasket 104 is received in the seat 102, the inner diameter of which is commensurate with that of the bore 101. The gasket 104 is constructed from a material or combination of materials having characteristics of inertness, low permeability, durability, and compressibility, such as rubber. The gasket 104 has a height just slightly greater than the depth of the seat 102, so that the gasket 104 protrudes slightly beyond the upper face 103. A thin film 105 is applied over the gasket 104 and is adhered and sealed to the upper face 103 of the lower aseptic connector 81. The thin film 105 completely overlies the gasket 104 with a continuous, closed-loop seal formed between the thin film 105 and the upper face 103 to act as a barrier to fluid migration. One having ordinary skill in the art will understand that the thin film 93 may be identified as a “first thin film” and the thin film 105 may be identified as a “second thin film,” and that such designations do not limit the number of thin films of the device 10. Similarly, one having ordinary skill in the art will understand that the bore 85, seat 90, and gasket 92 may be identified as a “first bore,” “first seat,” and “first gasket,” and that the bore 101, seat 102, and gasket 104 may be identified as a “second bore,” “second seat,” and “second gasket,” and that such designations do not limit the number of bores, seats, or gaskets of the device 10.
The upper and lower aseptic connectors 80 and 81 form a sterile fitting between the medicament reservoir 23 and the tubing set 64 allowing the reservoir 23 to be sterilized separately from the tubing 64 and then attached to the sterile tubing without affecting the sterility of either. Referring still to
Proximate to the slit 52 formed in the seam 45 between the rear top and rear bottom panels 15 and 16, a switch assembly 65 is carried. The switch assembly 65 is disposed on opposed sides of the two-ply ribbon 53. The switch assembly 65 is open when the two-ply ribbon 53 is interposed through the switch assembly 65, and the switch assembly 65 is closed when the two-ply ribbon 53 is not interposed through the switch assembly 65. Preferably, the switch assembly 65 includes an upper electrical contact 65a and a lower electrical contact 65b. The two-ply ribbon 53 is constructed of a non-conductive material, and so when the two-ply ribbon 53 is interposed between the upper and lower electrical contacts 65a and 65b, electrical communication between the upper and lower electrical contacts 65a and 65b is prevented. When the two-ply ribbon 53 is removed, such as would occur when the device 10 is moved from the storage state to the operational state by a medical professional pulling the two-ply ribbon 53 out of the device 10, the upper and lower electrical contacts 65a and 65b are placed in contact with each other and are coupled in electrical communication. Coupling the upper and lower electrical contacts 65a and 65b in electrical communication closes the switch assembly 65 and energizes the device 10.
Turning now to
The major tubing 120 is constructed of a material or combination of materials having characteristics of flexibility, fluid impermeability, and compressibility, such as polyvinylchloride, polyurethane, silicone, or the like. The major tubing 120 is routed around a pump unit 124 which acts on the major tubing 120 to draw medicament through the major tubing 120 from the reservoir 23. Referring to
Referring still to
Referring to both
From the force-sensing resistor 145, the minor tubing 122 bends downward and into the strain-relief coupling 123, to which the administration line 12 is coupled. The administration line 12 is a long, flexible, tubing terminating in the coupling 13, which is a luer fitting or the like, and is capped to maintain the sterility of the administration line 12.
A medical professional preparing the device 10 for use with a patient obtains the device 10 in a preferably packaged state. The device 10, including the housing 11, the components within the housing 11, and the administration line 12, are contained within the packaging. Such packaging need not necessarily be a sterilized packaging, given that the fluid communication path 62 was previously sterilized before assembly and will thus be sterile upon the opening of the packaging by the medical professional. The fluid communication path 62, being composed of the medicament reservoir 23, the aseptic connector assembly 63, the tubing set 64, and the administration line 12, is sterilized in two separate steps. In one step, the upper aseptic connector 80 is applied to the tip 72 of the reservoir 23. The upper aseptic connector 80, with its thin film 93 applied, prevents medicament from prematurely discharging from the reservoir 23. The medicament reservoir 23 is filled with a liquid medicament and then terminally sterilized by steam autoclave, together with the upper aseptic connector 80. In one manner of filling the medicament reservoir 23 with liquid medicament, the piston 74 is inserted into the barrel 70, which is open at the tip 72. Liquid medicament is supplied to the barrel 70 and the barrel 70 is then capped with the upper aseptic connector 80. In another manner of filling the medicament reservoir 23 with liquid medicament, the barrel 70 is capped with upper aseptic connector 80 at the tip 72, the liquid medicament is supplied to the barrel 70, and the piston 74 is then inserted into the barrel 70. The medicament reservoir 23 and the upper aseptic connector 80 together thus present a first sterilized part for assembly into the fluid communication path 62.
The lower aseptic connector 81, the tubing set 64, and the administration line 12 are sterilized independently from the medicament reservoir 23 and the upper aseptic connector 80. The major tubing 120 of the tubing set 64 is securely press fit onto the barb fitting 100 of the lower aseptic connector 81. One end of the reducing coupler 121 is then press fit into the major tubing 120, and the minor tubing 122 is press-fit over an opposed of the reducing coupler 121. The strain relief coupling 123 is fit into the free end of the minor tubing 122, and the administration line 12 is fit onto the strain relief coupling 123. The administration line 12 terminates with the coupling 13, which is preferably a luer fitting. Between the luer fitting coupling 13 and the thin film 105 on the upper aseptic connector 81, the tubing set 64 defines a closed system. The tubing set 64, the lower aseptic connector 81, and the administration line 12 are sterilized by Gamma radiation exposure and then applied into the housing 11. In some embodiments, the tubing set 64 assembled as described above will first be applied into the housing 11 and routed through the housing 11 and the pump unit 124, and then sterilized with exposure to Gamma radiation or ethylene oxide gas. In both manners, the medicament reservoir 23 and the upper aseptic connector 80 are sterilized separately from the lower aseptic connector 81, the tubing set 64, and the administration line 12.
With the medicament reservoir 23 and the upper aseptic connector 80 sterile, and with the lower aseptic connector 81, tubing set 64, and administration line 12 sterile, the fluid communication path 62 is ready for assembly by coupling and irreversibly engaging the upper and lower aseptic connectors 80 and 81, thus forming the aseptic connector assembly 63 installed and shown throughout the drawings. When the aseptic connector assembly 63 is formed, the two-ply ribbon 53 is threaded through the slit 52 in the housing 11, and the pull tab 54 is crimped, glued, or otherwise secured to the distal end of the two-ply ribbon 53. Once assembled in this manner, the sterility of the fluid communication path 62 is maintained and protected. The device 10 is then ready for shipping through distribution to medical professionals.
When a medical professional prepares the device 10 for use, the medical professional selects the device 10 containing the medicament needed for the procedure. For example, if Propofol must be administered to the patient, the medical professional obtains a device 10 containing Propofol. Alternatively, if Dexmedetomidine must be administered to the patient, the medical professional obtains a device 10 containing Dexmedetomidine. It is noted here that the device 10 is effective at delivering a variety of drug products, including liquid medicaments, and including, but not limited to Ofirmev® (Acetaminophen), Ketamine, Propofol, Precedex® (Dexmedetomidine), Fentanyl, Remifentanyl, Etomidate, Midazolam, Cubicin® (Daptomycin), Invanz® (Ertapenem), Polymyxin B, Acyclovir, Amikacin, Amphotericin B, Chloramphenicol, Vistide® (Cidofovir), Doxycycline, Erythromycin, Gentamicin, Synercid® (Quinupristin and Dalfopristin), Rifampin, Timentin® (Ticarcillin and Clavulanate), Tobramycin, Avastin® (Bevacizumab), Herceptin® (Trastuzumab), Cytoxan® (Cyclophosphamide), Neupogen® (Filgrastim), Vectibix® (Panitumumab), Cladribine, Dacarbazine, Remicade® (Infliximab), Foscarnet, Ganciclovir, Cerezyme® (Imiglucerase), Elelyso® (Taliglucerase alfa), Vpriv® (Velaglucerase alfa), Granisetron, Dopamine, Norepinephrine, Dobutamine, Milrinone, TPN (Total Parenteral Nutrition), IVIG (Intravenous Immunoglobulin), Gammagard® (Immune Globulin), Amrinone® (Inamrinone), Deferoxamine, Hemin, and Sodium Valproate, each of which is a medicament for which the dosage is set and administered depending on the weight of the patient. The device 10 is also effective at delivering a variety of drug products, including liquid medicaments, for which the dosage is set and administered depending on the height or surface area of a patient, including, but not limited to Azactam® (Aztreonam), Trimetrexate, 5FU (5-Fluorouracil), Rituxan® (Rituximab), Bleomycin, Erbitux® (Cetuximab), Velcade® (Vortezomib), Mylotarg® (Gemtuzumab Ozogamicin), Zevalin® (Ibritumomab Tiuxetan), Epirubicin, Fludarabine, Gemcitabine, Irinotecan, Oxalaplatin, Paclitaxel, Topotecan, Vinorelbine, Carboplatin, Carmustine, Cisplatin, Daunorubicin, Dexrazoxane, Docetaxel, Doxorubicin, Etoposide, Idarubicin, Ifosfamide, Camptosar, Mitomycin, Mitoxantrone, Leukine® (Sargramostim), Streptozocin, Vumon® (Teniposide), and Vinblastine.
After selecting the appropriate device 10, the medical professional removes the device 10 from its packaging and arranges the device 10 for use, such as by hanging from the hook 61 off of a stand proximate to the patient. The cap on the coupling 13 is removed and connected to a catheter already secured to the patient. In this manner, the fluid communication path 62 is coupled to the catheter on the patient with minimal opportunity for contamination. The medical professional then operates the device 10.
The device 10 is shipped in the storage state. In the storage state, the fluid communication path 62 is sterile and closed, but occluded by the thin films 93 and 105 on the upper and lower aseptic connectors 80 and 81. Further, in the storage state, the device 10 is not energized: no power is provided to the printed circuit board 144 or the motor 141, and the printed circuit board 144 or the motor 141 are electrically isolated from the battery supply 142. To operate the device 10, the medical professional must first both energize the device 10 and remove this occlusion. Energizing the device 10 is accomplished by pulling on the two-ply ribbon 53 to remove the two-ply ribbon 53, which simultaneously removes the occlusion. As the two-ply ribbon 53, consisting of both thin films 93 and 105, is drawn out of the housing, the thin films 93 and 105 are peeled off of the lower and upper faces 91 and 103, respectively, of the upper and lower aseptic connectors 80 and 81, respectively. Once the thin films 93 and 105 are removed from between the upper and lower aseptic connectors 80 and 81, the gaskets 92 and 104 are in direct and sealing contact with each other, still biased into compression with each other by the fingers 110. With the upper and lower aseptic connectors 80 and 81 maintained in coaxial alignment by the fingers 110, and the gaskets 92 and 104 thus maintained in coaxial alignment, the hole 86 in the upper aseptic connector 80 is coupled in fluid communication with the bore 101 of the lower aseptic connector 81.
In response to the two-ply ribbon 53 being removed from the housing 11, the upper and lower electrical contacts 65a and 65b proximate the aseptic connector assembly 63 are coupled, the switch assembly 65 is closed, and power is made available to the pump unit 124 from the battery supply 142. The printed circuit board 144 and the motor 141 are electrically coupled to the battery supply 142, and power is provided to the printed circuit board 144 and the motor 141. The device 10 is then ready for operation by the medical professional.
Depending on the medicament being administered to the patient, the medical professional will operate the pair of buttons 33 on the left side 24 of the device 10 and the pair of buttons 41 on the right side 25 of the device 10. If the medicament is one for which the dosage is dependent on weight, the medical professional will operate the pair of buttons 33 on the left side 24 of the device 10, incrementing or decrementing a weight value shown in the display 34 until it corresponds to the patient. Subsequently, the medical professional will operate the pair of buttons 41 on the right side 25 of the device 10, incrementing or decrementing a dosage value shown in the display 42 until it corresponds to the patient. Each time one of the buttons of the pair of buttons 33 or 41 is depressed, tactile, haptic or audible feedback is preferably provided to the medical professional. As seen in
Prior to connecting the device 10 to the patient for administration of the liquid medicament, the device 10 is preferably primed to remove any air from the fluid communication path 64. This can be accomplished by depressing the bolus button 44. Once the medical professional has set the device 10 to properly administer the medicament to the patient and the administration line 12 is properly connected to the patient, the medical professional depresses either the start/stop button 43 or the bolus button 44 to initiate operation of the device 10. The start/stop button 43 overlies and is electrically connected to the printed circuit board 144, and the logic on the printed circuit board 144 instructs the motor 141 to begin rotating. Depressing the start/stop button 43 once causes the printed circuit board 144 to issue an instruction to the motor 141 to begin rotating. Similarly, the bolus button 44 overlies and is electrically connected to the printed circuit board 144, and the logic on the printed circuit board 144 instructs the motor 141 to begin rotating according to a predetermined operation for administering a bolus volume of medicament. Depressing the bolus button 44 once causes the printed circuit board 144 to issue an instruction to the motor 141 to begin rotating.
The motor 141 rotates at a speed determined by the logic on the printed circuit board 144 based on the parameters displayed by windows 34 and 42 selected by the medical professional. Referring now to
Medicament is thus communicated through the major tubing 120 around the pump unit 124. The pump unit 124 draws medicament through the major tubing 120. In so doing, the downstream pump unit 124 applies a negative pressure in the major tubing 120 to draw medicament out of the reservoir 23. The pump unit 124 thus pulls medicament out of the reservoir 23 and through the major tubing 120. The pump unit 124 further pushes medicament out of the major tubing 120, into the minor tubing 122, and out the administration line 12 to the patient.
A preferred embodiment is fully and clearly described above so as to enable one having skill in the art to understand, make, and use the same. Those skilled in the art will recognize that modifications may be made to the described embodiment without departing from the spirit of the invention. To the extent that such modifications do not depart from the spirit of the invention, they are intended to be included within the scope thereof.
This application is a divisional of and claims the benefit of prior U.S. patent application Ser. No. 14/593,720, filed Jan. 9, 2015, which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
3909910 | Rowe et al. | Oct 1975 | A |
4019512 | Tenczar | Apr 1977 | A |
4137913 | Georgi | Feb 1979 | A |
4861335 | Reynolds | Aug 1989 | A |
5244463 | Cordner et al. | Sep 1993 | A |
5324258 | Rohrbough | Jun 1994 | A |
5538399 | Johnson | Jul 1996 | A |
5906589 | Gordon et al. | May 1999 | A |
6109895 | Ray et al. | Aug 2000 | A |
6655655 | Matkovich | Dec 2003 | B1 |
6835049 | Ray | Dec 2004 | B2 |
7169128 | Kriesel et al. | Jan 2007 | B2 |
7220244 | Kriesel | May 2007 | B2 |
7220245 | Kriesel | May 2007 | B2 |
7316245 | Bivin | Jan 2008 | B2 |
7470253 | Kriesel et al. | Dec 2008 | B2 |
7481244 | Bivin | Jan 2009 | B2 |
7513273 | Bivin | Apr 2009 | B2 |
7694938 | Kriesel et al. | Apr 2010 | B2 |
7735522 | Bivin et al. | Jun 2010 | B2 |
7776006 | Childers et al. | Aug 2010 | B2 |
7789853 | Kriesel | Sep 2010 | B2 |
7828770 | Bivin et al. | Nov 2010 | B2 |
7828772 | Kriesel et al. | Nov 2010 | B2 |
7833195 | Kriesel et al. | Nov 2010 | B2 |
7837653 | Kriesel et al. | Nov 2010 | B2 |
7896843 | Kriesel et al. | Mar 2011 | B2 |
D636271 | Kriesel | Apr 2011 | S |
7993304 | Kriesel et al. | Aug 2011 | B2 |
8029468 | Kriesel et al. | Oct 2011 | B2 |
8057435 | Kriesel et al. | Nov 2011 | B2 |
8083503 | Voltenburg, Jr. et al. | Dec 2011 | B2 |
8083717 | Kriesel | Dec 2011 | B2 |
8100890 | Kriesel et al. | Jan 2012 | B2 |
8105280 | Iddan et al. | Jan 2012 | B2 |
8114052 | Bivin et al. | Feb 2012 | B2 |
8123723 | Bivin et al. | Feb 2012 | B2 |
8133204 | Kriesel | Mar 2012 | B1 |
8142398 | Kriesel et al. | Mar 2012 | B1 |
8197445 | Kriesel et al. | Jun 2012 | B2 |
8211059 | Kriesel et al. | Jul 2012 | B2 |
8226609 | Kriesel et al. | Jul 2012 | B2 |
8231575 | Kriesel | Jul 2012 | B2 |
8287521 | Kriesel et al. | Oct 2012 | B2 |
8292848 | Kriesel et al. | Oct 2012 | B2 |
8292876 | Kriesel et al. | Oct 2012 | B2 |
8317753 | Kriesel et al. | Nov 2012 | B2 |
8361009 | Lee et al. | Jan 2013 | B2 |
8377043 | Kriesel et al. | Feb 2013 | B2 |
8388571 | Joshi et al. | Mar 2013 | B2 |
8388578 | Joshi et al. | Mar 2013 | B2 |
8403887 | Kriesel et al. | Mar 2013 | B2 |
8480656 | Kriesel | Jul 2013 | B2 |
8622965 | Kriesel | Jan 2014 | B2 |
8672885 | Kriesel et al. | Mar 2014 | B2 |
8821454 | Kriesel et al. | Sep 2014 | B2 |
20030030272 | Johnson et al. | Feb 2003 | A1 |
20050151105 | Ryan et al. | Jul 2005 | A1 |
20060030838 | Gonnelli | Feb 2006 | A1 |
20060052322 | Roth et al. | Mar 2006 | A1 |
20070235083 | Glugos | Oct 2007 | A1 |
20090093793 | Gross et al. | Apr 2009 | A1 |
20090124994 | Roe | May 2009 | A1 |
20100021230 | Olivier | Jan 2010 | A1 |
20110282284 | Kriesel et al. | Nov 2011 | A1 |
20110282300 | Kriesel et al. | Nov 2011 | A1 |
20120130341 | Whitley | May 2012 | A1 |
20130218123 | Beiriger | Aug 2013 | A1 |
20130296792 | Cabiri | Nov 2013 | A1 |
20130296803 | Kriesel | Nov 2013 | A1 |
20130331823 | Askem et al. | Dec 2013 | A1 |
20140058318 | Yodfat et al. | Feb 2014 | A1 |
20140213975 | Clemente et al. | Jul 2014 | A1 |
20140241923 | Nzike et al. | Aug 2014 | A1 |
20140296787 | Agard et al. | Oct 2014 | A1 |
20140301913 | Williams et al. | Oct 2014 | A1 |
20150174304 | Askem et al. | Jun 2015 | A1 |
20160144094 | Margolin et al. | May 2016 | A1 |
Number | Date | Country |
---|---|---|
S49129223 | Dec 1974 | JP |
S63230175 | Sep 1988 | JP |
2011002853 | Jan 2011 | WO |
Number | Date | Country | |
---|---|---|---|
20180243500 A1 | Aug 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14593720 | Jan 2015 | US |
Child | 15968150 | US |